National Cancer Drugs Fund List - Approved

Transcription

1 National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer Advanced Adenocarcinoma Pancreas Advanced Renal Cell Carcinoma CLL Low grade Lymphoma Relapsed Low grade Lymphoma YEAR AGREED IPFR NOT AGREED IPFR <5 <5 - <5 < < < COMMENTS - -

2 Rituximab refractory Low grade Lymphoma Mantle cell Non Hodgkin s Lymphoma Relapsed Mantle cell Non Hodgkin s Lymphoma Relapsed Multiple Myeloma Recurrent or metastatic Cervical Cancer Advanced Breast Cancer First line treatment of Advanced Colorectal Cancer with a single agent fluoropyramidine First line treatment of Advanced Colorectal Cancer with combination chemotherapy < this this and <5 recorded for metastatic Breast Cancer < 5 recorded for metastatic Colorectal Cancer. < 5 for metastatic Colorectal Cancer and <5 recorded for Colorectal Cancer. < 5 recorded for metastatic Colorectal Cancer. < 5 for metastatic Colorectal Cancer and <5 recorded for Colorectal Cancer.

3 Bortezomib Bortezomib Bortezomib Bortezomib Second or third line treatment of Advanced Colorectal Cancer Third line treatment of low grade Gliomas of Childhood First line treatment of Advanced Epithelial Ovarian, fallopian tube, or primary peritoneal Cancer Second line treatment of Advanced Epithelial Ovarian, fallopian tube, or primary peritoneal Cancer Relapsed/Refractory Mantle Cell Lymphoma Bortezomib naïve relapsed Multiple Myeloma Relapsed Multiple Myeloma Relapsed Waldenstrom s Macroglobulinaemia this this Bosutinib Refractory chronic phase CML < 5 recorded for metastatic Colorectal Cancer. < 5 for metastatic Colorectal Cancer and <5 recorded for Colorectal Cancer., and less than 5 recorded for Ovarian Cancer, and <5 recorded for Ovarian Cancer

4 Bosutinib Bosutinib Bosutinib Bosutinib Bosutinib Brentuximab Brentuximab Cabazitaxel Refractory accelerated phase CML Refractory blast crisis CML Chronic phase CML Accelerated phase CML Blast crisis CML where there is intolerance of treatment Refractory systemic anaplastic Lymphoma Relapsed or refractory CD30+ Hodgkin Lymphoma Castrate resistant metastatic Prostate Cancer <5 - - and <5 recorded for HL

5 Cetuximab Cetuximab Clofarabine Clofarabine Crizotonib Dabrafenib Dasatanib Enzalutamide Advanced Head and Neck Cancer Colorectal/ metastatic Colorectal Cancer all indications listed on CDF list Relapsed refractory ALL Relapsed refractory AML Treatment of ALK positive advanced or metastatic non Small Cell Lung Cancer Unresectable or metastatic Melanoma etc All indications listed on CDF list Castrate resistant metastatic Prostate Cancer - -,, <5 recorded Eribulin Advanced Breast Cancer and

6 Everolimus Everolimus Everolimus Imatinib Lapitinib Lenalidomide Lenalidomide Nelarabine Advanced Breast Cancer Pancreatic neuroendocrine Carcinoma Metastatic Renal Cell Carcinoma Adjuvant treatment of Gastrointestinal Stromal Tumour Advanced Breast Cancer Second line treatment for Multiple Myeloma Treatment of Myelodysplastic Syndromes etc. Refractory T Cell ALL or NHL < <5 - < < <5 recorded for Metastatic Breast Cancer <5 recorded for Renal Cancer <5 recorded for Breast Cancer

7 Ofatumumab Panitumumab Pazopanib Pegylated Liposomal Doxorubicin Pemetrexed Pemetrexed Peptide Receptor Radionucleotide Therapy Pertuzumab CLL Metastatic Colorectal Cancer Advanced Non adipocytic soft tissue Sarcoma Named Sarcomas Maintenance treatment of Advanced Non Squamous Non Small Cell Lung Cancer Second line treatment of Advanced Non Squamous Non Small Cell Lung Cancer Advanced Neuroendocrine Tumours First line treatment of Advanced Metastatic Breast Cancer < <5 - Pomalidomide Relapsed and refractory Multiple <5 recorded for Leiomyosarcoma

8 Ponatinib Ponatinib Radium -223 Dichloride Regorafenib Ruxolitinib Sorafenib Sorafenib Sunitinib Myeloma CML with T315I mutation Ph+ ALL with T315I mutation Castration resistant Prostate Cancer with bone metastases Advanced GIST after failure of Imatinib and Sunitinib Symptomatic Splenomegaly in various Myelofibrosis First line treatment of Advanced Hepatocellular Carcinoma Treatment of Follicular or Papillary Thyroid Cancer Pancreatic Neuroendocrine Carcinoma <5 -

9 Temsirolimus Trastuzumab Vandetinib Vismodegib Advanced renal Cell Carcinoma HER2 + locally advanced or unresectable or metastatic Breast Cancer Medullary Thyroid Cancer Locally Advanced or metastatic Basal cell Carcinoma National Cancer Drugs Fund List Not Approved No applications were received for the following drugs :- Afatanib Albumin bound paclitaxel for relapsed refractory classical Hodgkin s Lymphoma treatment of progressive (recurrent) Glioblastoma after initial treatment with radiotherapy and Temozolomide Bortezomib Pemetrexed Ponatinib for CML Regorafenib Trabectedin Vinflunine

10 Applications were received for the following drugs however the approved criteria, applied by NCDF, are not recorded on the IPFR Database: in combination with Rituximab for the treatment of relapsed/ refractory DLBCL for remaining indications (not shown in list above) Brentuximab Lapitinib Panitumumab Ponatinib for Ph+ ALL Sorafenib